Spur Therapeutics’ Post

Going to CRT - Cardiovascular Research Technologies? Thomas E. Waggoner, DO, FACC, FSCAI, FSVM, RPVI will be presenting 30-day data from the DurAVR™ THV US Early Feasibility Study (EFS), and Rishi Puri will be presenting the latest DurAVR THV FIH study results and an analysis of the EFS data. Mark your calendars! #CRT2024 Can’t attend? Sign up for clinical data updates here: https://lnkd.in/gur9JPeX DurAVR™ INVESTIGATIONAL USE ONLY. NOT AVAILABLE FOR COMMERCIAL SALE. EU: Exclusively for clinical investigations. US: CAUTION – Investigational Device. Limited by Federal (or United States) law to investigational use.

FPFV achieved for our Ph1/b clinical trial (GRT-001 monocyte-depleting mAb)

// NASH/MASH clinical trials // Why is integrating PROs into studies on NASH crucial? Kayentis has the tools and experience to make your NASH clinical trials successful! #kayentis #eCOA #ePRO #DCT #NASH

Check out Sarah Bly's and Matt Cooper's interview with Clinical Trials Arena to learn more about cross-border enrollment in European clinical trials!

Register today! Study Overview webinars are being offered to review our #breastcancer clinical trial, NRG-BR008 - the HERO Study (Her2 Radiation Optimization). Refer to the memo posted on the CTSU for details on how to register. #bcsm #BreastCancerAwarenessMonth

The Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) and the CONsolidated Standards Of Reporting Randomised Trials (CONSORT) are two pivotal tools in driving comprehensive and transparent disclosure of essential content within trial protocols and reports. This paper (DEFINE Study) aims to overcome the shortcomings of SPIRIT and CONSORT in addressing the characteristics of Early phase dose-finding (EPDF) trials (Also typically referred to as phase I, I/II, or dose-escalation trials). https://lnkd.in/etn_NB_n

Exciting news for the medical community! Thrombolytic Science's novel dual fibrinolytic treatment with mutant prourokinase (mproUK) is set to undergo a clinical trial later this year. The British Regulatory Agency, the MHRA, has accepted TSI's request for a clinical trial authorization, paving the way for an open label, randomized pilot clinical Phase II study. This study will explore the safety of mproUK preceded by tissue plasminogen activator and resulting early epicardial and microvessel patency in patients presenting with an ST-elevation myocardial infarction (STEMI). Stay tuned for updates! #CTA #MHRA #STEMI #clinicaltrial #ThrombolyticScience #mproUK #dualfibrinolytic

Join Dr. Kremyankskya for dinner to learn more about the VERFIY study!

New Topline Efficacy Data from the enVVeno Medical VenoValve® Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024 https://bit.ly/4aQUeII #CVI #ChronicVenousInsufficiency #VenousDisease

With the presentation of MODULAR ATP and APPRAISE ATP clinical trial data, it’s an exciting day here at #HRS2024. Together, these data reinforce the promise of the groundbreaking mCRM System, and illustrate a clear path forward for physicians to offer therapies that prevent sudden cardiac death and deliver antitachycardia pacing (ATP) for the patients who benefit from it. The investigational mCRM System offers a potential upgrade pathway for patients currently implanted with the EMBLEM™ S-ICD System who develop a need for ATP or pacing, allowing physicians to tailor therapy to a patient’s individual needs. Congratulations to the team at Boston Scientific who made the study a success, principal investigators Reinoud Knops M.D. PhD and Claudio Schuger, and those who have supported these important studies! Congratulations also on the simultaneous publication of the MODULAR ATP results in the New England Journal of Medicine, where the results are now available: https://lnkd.in/eEE72t77 * Caution: Investigational Device. Limited by US law to investigational use only. Not available for sale.